Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NGR015 phase III trial of NGR-hTNF plus investigator's choice versus placebo plus investigator's choice in previously treated malignant pleural mesothelioma
2009-016879-29Phase 3Completed
- Sponsor
- MolMed
- Start
- Dec 2009
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pleural mesothelioma comparing NGR-hTNF plus best investigator's choice with Placebo plus best investigator's choice (2 arms). Primary endpoint: overall survival. Started Dec 2009; status: completed.
02
Drugs
NGR-TNF
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on 2009-016879-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016879-29.